Catch up on all the biggest pharma news to hit the industry last month, spanning from new acquisitions, insights on the NHS ...

Acute respiratory distress syndrome (ARDS) is a neutrophil-dominant disorder with no effective pharmacological therapies. While the cyclin-dependent kinase inhibitor AT7519 induces neutrophil ...

Studies have shown that such pathogenesis is related to abnormal cell cycle progression. The expression levels of cyclins, cyclin-dependent kinases (CDKs), and CDK inhibitors as well as functions of ...

Among the many impactful sessions, a symposium titled ‘Incorporating Novel Treatment Insights for Estrogen Receptor-Positive (ER+) Early Breast Cancer Patients’ garnered particular attention.

349 followers https://aws.amazon.com/cdk [email protected] ...

A Blueprint Medicines Corp. patent describes new cyclin-dependent kinase 2 (CDK2) inhibitors reported to be useful for the treatment of cancer.

Inotuzumab Ozogamicin and Low-Intensity Chemotherapy in Older Patients With Newly Diagnosed CD22+ Philadelphia Chromosome–Negative B-Cell Precursor Acute Lymphoblastic Leukemia We enrolled 16 patients ...

A TYK Medicines Inc. patent discloses tricyclic compounds acting as CDK2/cyclin E1 inhibitors reported to be useful for the treatment of cancer.

In an interview with Targeted Oncology, Erika Hamilton, MD, discussed emerging endocrine therapies that are advancing breast ...